Abstract
Malignant peripheral nerve sheath tumors (MPNST) compose a fraction of all soft tissue sarcomas, but are life-threatening and present difficult diagnostic and therapeutic challenges. Benign peripheral nerve sheath tumors, including schwannomas or neurofibromas, can often be managed conservatively unless symptomatic. MPNSTs require aggressive multimodality treatment (surgery, radiation therapy, ± chemotherapy). MPNSTs can arise from pre-existing neurofibromas in patients with neurofibromatosis type 1 (NF1) or can develop sporadically in the general population. Peripheral nerve sheath tumors are often pathologically heterogeneous or in difficult anatomic locations often making needle biopsy unreliable or unfeasible. Current standard imaging of these tumors rely on computed tomography (CT) or magnetic resonance imaging (MRI), both of which characterize size and local invasiveness, but do not provide reliable insight into the presence of malignant transformation. Clinical manifestations of malignant transformation classically rely on reported symptoms of new neurological deficits, rapid increase in size, change in palpated density from soft to hard, and unremitting pain. Investigations into the glycolytic phenotype of peripheral nerve sheath tumors with [18F] 2-Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) have been performed to identify potential areas of malignant degeneration. Lower tumor FDG uptake has proven to correlate with benign peripheral nerve sheath tumors, which can be distinguished from the high FDG uptake of its malignant counterpart, MPNST. Clinicians may employ this imaging modality to help identify MPNSTs, guide biopsies, direct therapies, measure response to treatment, and survey for tumor recurrence.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF (2004) Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. Am J Roentgenol 182(4):971–974
Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA (2008a) Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med 49(10):1579–1584
Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15(8):2856–2863
Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC (2010a) Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116(2):451–458
Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J (2010b) Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med 51(8):1174–1181
Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA (2008b) Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 49(7):1038–1046
Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M, Mautner VF (2006) Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 33(4):428–432
Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer section sign G, Lehnert T (2003) Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29(6):536–541
Chander S, Westphal SM, Zak IT, Bloom DA, Zingas AP, Joyrich RN, Littrup PJ, Taub JW, Getzen TM (2004) Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med 29(7):415–418
Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, Im JG (2006) False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 7(1):57–69
Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57(10):2006–2021
Eary JF, O’Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, Conrad EU (2002) Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 29(9):1149–1154
Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39(5):311–314
Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14(3):715–720
Ferner RE (2010) The neurofibromatoses. Pract Neurol 10(2):82–93
Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O’Doherty M (2008) [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 19(2):390–394
Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res 62(5):1573–1577
Fisher MJ, Basu S, Dombi E, Yu JQ, Widemann BC, Pollock AN, Cnaan A, Zhuang H, Phillips PC, Alavi A (2008) The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol 87(2):165–171
Korf BR (1999) Plexiform neurofibromas. Am J Med Genet 89(1):31–37
Kostakoglu L, Agress H Jr, Goldsmith SJ (2003) Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23(2):315–340
Landry CS, Waguespack SG, Perrier ND (2009) Surgical management of nonmultiple endocrine neoplasia endocrinopathies: state-of-the-art review. Surg Clin North Am 89(5):1069–1089
Li CS, Huang GS, Wu HD, Chen WT, Shih LS, Lii JM, Duh SJ, Chen RC, Tu HY, Chan WP (2008) Differentiation of soft tissue benign and malignant peripheral nerve sheath tumors with magnetic resonance imaging. Clin Imaging 32(2):121–127
Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6(3):E81–86
MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES (2005) Diagnostic criteria for schwannomatosis. Neurology 64(11):1838–1845
Mautner VF, Friedrich RE, von Deimling A, Hagel C, Korf B, Knöfel MT, Wenzel R, Fünsterer C (2003) Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma. Neuroradiology 45(9):618–625
Miki Y, Ngan S, Clark JC, Akiyama T, Choong PF (2010) The significance of size change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol 36(7):678–683
Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68(5):1110–1118
Shah N, Sibtain A, Saunders MI, Townsend E, Wong WL (2000) High FDG uptake in a schwannoma: a PET study. J Comput Assist Tomogr 24(1):55–56
Steinhart H, Triebswetter F, Wolf S, Gress H, Bohlender J, Iro H (2003) Growth of sporadic vestibular schwannomas correlates with Ki-67 proliferation index. Laryngorhinootologie 82(5):318–321
Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM (2005) Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65(2):205–211
Warbey VS, Ferner RE, Dunn JT, Calonje E, O’Doherty MJ (2009) [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36(5):751–757
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Shurell, E., Eilber, F.C. (2012). Peripheral Nerve Sheath Tumors: Diagnosis Using Quantitative FDG-PET. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 4. Tumors of the Central Nervous System, vol 4. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1706-0_17
Download citation
DOI: https://doi.org/10.1007/978-94-007-1706-0_17
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-1705-3
Online ISBN: 978-94-007-1706-0
eBook Packages: MedicineMedicine (R0)